PHILADELPHIA, June 20, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company specializing in complex studies in therapeutic areas such as oncology, central nervous system (CNS) and rare diseases, has selected Irena Lerentracht Webster to join its board of directors. Webster is an experienced global leader in drug development with more than two decades of experience at the sponsor, chief risk officer and site level. She has led the strategy and execution of global clinical trials in a wide variety of therapeutic areas, including neurology, psychiatry, oncology, cardiology, and rare diseases, contributing to multiple NDAs and sNDAs. Click to tweet.
Webster currently serves as Vice President, Head of Development Program Strategy and Operations for Arkuda Therapeutics, a biotechnology company that focuses on neurodegenerative diseases. Prior to that, he led the clinical operations and biometrics teams at FORMA Therapeutics (now a Novo Nordisk company) through a global sickle cell program, as well as the approval of olutasidanib (Rezlidhia™) for the treatment of myeloid leukemia. acute with IDH1 mutation. He has also held senior clinical development and operations roles at Sage Therapeutics and Alkermes.
"Irena brings a wealth of experience and insight into all aspects of clinical development and is known for being a change leader and practice innovator," said Jagath Wanninayake, CEO of Suvoda. "Throughout his career, he has demonstrated a commitment to the science of clinical research, while also focusing on the human element, particularly the site and patient experience. His unique perspective on the Suvoda dashboard will make a significant contribution to our ability to deliver innovative technology solutions that reduce the burden on clinical trial teams and the patients they serve."
In addition to joining the board of directors, Webster also serves on Suvoda's Customer Advisory Board (CAB).
"Suvoda has a culture of authenticity, curiosity, passion, and excellence that is immediately apparent to customers. The leadership is extraordinarily customer-focused, keen to understand and participate, in an effort to help someone like me, in the role of sponsor, do my job better," Webster said. "These characteristics and culture are what motivated me to accept when I was asked to join the board. I am proud to collaborate with some of the brightest minds in the eClinical space, to make a difference in the way teams of clinical trials care for patients.
Webster's appointment follows Suvoda's recent launch of the Suvoda platform, which integrates IRT, eConsent and eCOA solutions to provide drug trial sponsors and sites with a seamless way to manage complex, mission-critical and risk-sensitive moments. time in clinical trials.
Webster earned his master's degree in public health from New York Medical College.
About Suvoda Suvoda is a global clinical trials technology company specializing in complex life support studies in therapeutic areas such as oncology, central nervous system (CNS) and rare diseases. Founded in 2013 by experts in eClinical technologies, Suvoda enables clinical trial professionals to manage the most pressing moments in the most urgent trials through advanced software solutions delivered on a single platform. Headquartered outside of Philadelphia, Suvoda also has offices in Portland, Oregon, Barcelona, Spain, Bucharest, Romania, and Tokyo, Japan. The company consistently boasts a Net Promoter Score (NPS) close to 70, which is well above the tech industry average of 50, and has been selected by trial sponsors and CROs to support more than 1,000 trials in 80 countries. For more information, visit suvoda.com. Follow Suvoda on Twitter and LinkedIn.
For information, contact:
Mara Conklin, (847) 340-6823mconklin@teamclarus.com
Kathy Zoeller, (312) 485-2422kathy@mattsonpr.com
Logo - https://mma.prnewswire.com/media/1759317...
View original content: https://www.prnewswire.com/news-releases/suvoda-amplia-la-junta-directiva-con-la-incorporacion-de-la-veterana-de-ensayos-clinicos-irena-webster-301853028.html
